

Ceramic/metal biocidal nanocomposites for bone-related applications

Miriam Miranda^{a*}, Adolfo Fernández^b, Sonia Lopez-Esteban^a, Francisco Malpartida^c,

José S. Moya^d, Ramón Torrecillas^a

^a*Centro de Investigación en Nanomateriales y Nanotecnología (CINN-CSIC-UO-PA), Llanera, Spain.*

^b*ITMA Materials Technology, Llanera, Spain.*

^c*Centro Nacional de Biotecnología (CNB-CSIC), 28049, Cantoblanco, Spain.*

^d*Instituto de Ciencia de Materiales de Madrid (ICMM), Consejo Superior de Investigaciones Científicas (CSIC), Cantoblanco, Spain.*

*Corresponding autor. CINN-CSIC. Parque Tecnológico de Asturias, 33428, Llanera, Spain. Tel.: +34-985.98.00.58. Fax: +34-985.26.55.74. Email: m.miranda@cinn.es

ABSTRACT

Hydroxyapatite/silver nanocomposites have been designed and synthesized as an engineering material for biomedical applications. The hydroxyapatite matrix was synthesized by a sol-gel method and, subsequently, the Ag nanoparticles were deposited by heterogeneous precipitation followed by two different reduction routes: thermal or chemical. Both sets were studied and compared and, in all cases, the metal nanoparticles appear perfectly isolated and attached to the surface of the hydroxyapatite. The average metal particle size is below 10 nm, allowing an important contact surface between silver and the microorganisms. The antimicrobial behavior against common bacteria showed a high effectiveness, well above the commercial level, as well as against yeast, in the case of the chemically reduced sample. Due to the nanocomposite microstructure, only a negligible portion of metal was released to the lixiviated liquid after the biocide tests, minimizing the risk of toxicity. These nanocomposites offer a solution to the infections on the surface of implants, one of the main problems in reaching a suitable level of osseointegration.

Keywords: hydroxyapatite, silver, antibacterial, nanoparticle, composite.

1. Introduction

Nowadays, much effort is being devoted in the field of nanomaterials to the fabrication of a new generation of reliable and longer-lasting implants for joint replacement [1]. Unfortunately, the appearance of infection in the tissues surrounding an implant is a factor that often decreases the success and life-span of the artificial device. The prevention of a biofilm formation is crucial in order to avoid complications due to bacterial infections after the implant positioning [2], for example, osteomyelitis and prosthetic joint infections are some of the pathogenesis that can take place in the case of orthopaedic infections in the presence of biofilm [3, 4].

A remarkable new approach to try to solve this problem has focused on ceramic-matrix composites with metal particles embedded as a second phase, which have been proved to present mechanical and functional features which are useful for a wide range of applications [5-10]. It deals specifically with a hydroxyapatite matrix [HA, $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$] with embedded silver nanoparticles (HA/Ag) [11, 12]. This nanocomposite has been proposed for several reasons. Firstly, hydroxyapatite works out as the ceramic matrix, as it is the main inorganic phase in bones and is osseointegrator, which makes it a candidate material for biomedical applications [13] (implants [14-16], drug carriers [17-19], bone tissue engineering scaffolds [20-22], etc). Secondly, silver has been the metal selected, as it has been for a long time a well known antibacterial, exhibiting activity against a broad spectrum of different bacteria, and even some bacterial strains with resistance against antibiotics [23, 24]. The preliminary studies of the behavior of these nanocomposites against some specific microorganisms has shown a promising biocidal effect [11, 12] and the need to be studied in depth from multiple

1 points of view: from the synthesis and preparation of the material up to the study of the
2
3 interaction material/microorganism.
4

5
6 In this work, two different routes to obtain HA/Ag nanocomposites are
7
8 proposed. The physico-chemical properties of the resulting samples are compared and
9
10 the antimicrobial benefits of the composites are evaluated against bacteria and yeast.
11
12 Furthermore, the interaction of the nanoparticles with the microorganisms is studied in
13
14 detail.
15
16

17 18 19 **2. Materials and methods** 20

21 22 *2.1. Samples preparation* 23


24
25
26 The HA nanopowder was prepared *in situ* in the laboratory following the sol-gel
27
28 route resumed in the flow chart in Fig. 1A and previously described elsewhere [11].
29
30

31
32 Regarding the preparation of the HA-Ag composite nanopowder, two different
33
34 methods were followed depending on the reduction treatment. In the first procedure, the
35
36 precursor was thermally reduced (samples labeled as *HA/nAg-Th*), while in the second
37
38 case a chemical reduction was used (*HA/nAg-Ch* samples). In both cases, the first step
39
40 was the preparation of a HA aqueous suspension (9 wt.% of solids loading); a dispersant
41
42 (*Dolapix CE-64*) was added to improve the suspension stability at pH=7. At this pH
43
44 there was a compromise, as on one hand no precipitation of the silver precursor took
45
46 place and on the other hand, the solubility of calcium from the HA was extremely low,
47
48 as shown in Fig. 2.
49
50
51
52

53
54
55 The suspension was ball milled for 24 hours and, subsequently, the silver
56
57 precursor suspension was dropped to reach a concentration of silver of 1 wt.% in the
58
59
60
61
62
63
64
65

1 final product. In the case of HA/nAg-Th, as shown in Fig. 1B, the pH was adjusted to 9
2
3 by dropping a NaOH aqueous solution 1M to precipitate Ag^+ as Ag_2O , according to the
4
5 potential-pH diagram in aqueous solution for silver [25]. The material is centrifuged at
6
7 3500 rpm and dried. The reduction takes place at 350°C for 2 hours in a controlled
8
9 atmosphere of H_2/Ar 10/90.
10
11

12
13
14 In the case of the HA/nAg-Ch sample, there was a chemical reduction with
15
16 sodium borohydride (NaBH_4 , *Sigma-Aldrich*) as reductor agent, as described elsewhere
17
18 [12]. It was added quickly into the stirred suspension with the HA and silver precursor
19
20 to promote the precipitation of Ag^0 according to the next reactions:
21
22



32
33 Afterwards, as in the case of HA/nAg-Th, the powder was centrifuged and dried.
34
35 Different dry treatments were compared in the case of HA/nAg-Ch to optimize the
36
37 nanoparticle size distribution; three temperatures (60 , 150 and 250°C , respectively) and
38
39 a lyophilization treatment were compared. All the steps in both procedures to add the
40
41 silver were carried out in a dark room to avoid the spontaneous reduction of silver
42
43 cations due to the presence of light.
44
45

46 47 48 2.2. Characterization techniques 49

50
51 A thermogravimetric analysis (TGA) was carried out in TGA using *TA-*
52
53 *Instruments* Model SDT 2960). The particle size distribution was determined in a
54
55 *Coulter LS 13320* particle size analyzer equipped with a laser source ($\lambda = 750$ nm). X-
56
57
58
59
60
61
62
63
64
65

1 ray powder diffraction (XRD) patterns were registered using a *Bruker D8 Advance*
2
3 diffractometer with a Cu K_α radiation source at a scan speed of 0.5°/min. The
4
5 transmission electron microscopy (TEM) images were obtained with a Field Emission
6
7 TEM *FEI Tecnai F20*. UV-vis spectroscopy was performed using a *Cary 4000* uv-vis
8
9 spectrophotometer.
10

11
12
13 The biocide activity was measured against three different microorganisms:
14
15 *Escherichia coli JM 110* (Gram-negative bacteria), *Micrococcus luteus* (Gram-positive
16
17 bacteria) and *Issatchenkia orientalis* (yeast). The media used were Luria Bertani (LB)
18
19 for *Escherichia coli JM 110* and *Micrococcus luteus*, and for *Issatchenkia orientalis* it
20
21 was yeast extract dextrose (YEPD). 10 μL of a saturated suspension according to the
22
23 microorganism to be studied were added to 1 mL of the corresponding medium.
24
25 Subsequently, an aqueous suspension of each HA/nAg sample was prepared with a
26
27 concentration of 20 wt.%, and 150 μL were added to the medium with the
28
29 microorganisms. For each test a silver free media was used as a control (the sample
30
31 suspension was replaced by water). The inoculums were incubated at 30 °C with
32
33 horizontal shake for 48 h. The number of colonies was counted every 24 h.
34
35
36
37
38
39
40
41

42 **3. Results and discussion**

43 44 45 *3.1. HA nanopowders*

46
47
48 The first goal was to determine the temperature of crystallization of HA from the
49
50 thermogravimetric analysis of the dried hydroxyapatite gel (Fig. 3A). The test was
51
52 carried out in air, at a heating rate of 5°C/min in the range 25-1000°C. An endothermal
53
54 peak was observed around 550°C and it was initially associated with the crystallization
55
56
57
58
59
60
61
62
63
64
65

1 of HA. In order to test this hypothesis, several calcination temperatures were tested to
2
3 study the resulting crystallinity: 300°C, 475°C and 550°C.
4
5

6
7 The resulting phases were analyzed by XRD, showing a clear difference in
8
9 crystallinity between all the samples (Fig. 3B). Thus, the powder resulting at 300°C
10
11 corresponded to totally amorphous HA; the powder calcined at 475°C was partially
12
13 amorphous, showing poorly defined peaks; finally, the powder resulting at 550°C
14
15 corresponded to pure, stoichiometric and crystalline HA. For this reason, the
16
17 temperature chosen for the heat treatment was 550°C.
18
19
20
21

22 The granulometric analysis (Fig. 4A) shows a narrow particle size distribution
23
24 with an average particle size around 125 nm, in agreement with TEM observations (Fig.
25
26 4B). The parameter d_{90} indicates that 90% of the HA particles present a size below 155
27
28 nm. It is also possible to differentiate the crystallographic planes (Fig. 4B). In
29
30 summary, the hydroxyapatite obtained by the followed sol-gel route was pure,
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3.2. HA/nAg nanocomposites

66
67 In order to verify whether the final size distribution of the silver nanoparticles
68
69 was affected or not by the method of drying the powders, different dry temperatures
70
71 were tested in the oven and the results were also compared with those obtained by
72
73 lyophilization (Table 1). This study was carried out with the sample chemically reduced
74
75 (HA/nAg-Ch) because it will no suffer any further heat treatment and, therefore, is more
76
77 sensitive to the dry process. As shown in Table 1, the size obtained by lyophilization is
78
79 lower than any of those obtained by a thermal treatment. Therefore, lyophilization
80
81 hinders the nanoparticle agglomeration better than the thermal treatments. According to
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

1 these results, both sets of samples (HA/nAg-Th, HA/nAg-Ch) were dried by
2
3 lyophilization, in order to keep the metal particle size as small as possible. Thus, the
4
5 metallic surface exposed to the microorganisms will increase, which is expected to
6
7 enhance the bactericidal activity of the composite.
8
9

10
11 In the XRD analysis of the samples, no other phases other than HA and Ag were
12
13 detected (Fig. 5A). It is important to emphasize that neither destabilization nor
14
15 dissolution of hydroxyapatite took place during the synthesis of Ag nanoparticles.
16
17
18
19

20 One tool commonly used to characterize nanoparticles is surface plasmon
21
22 resonance. In the particular case of silver nanoparticles, the main peak is normally
23
24 presented at around 420 nm. Depending on the surroundings of the nanoparticles and
25
26 their size and shape distribution, the position and shape of the band can vary [26, 27].
27
28 This can be seen in Fig. 5B, which shows the UV-VIS spectrum for HA/nAg-Th and
29
30 HA/nAg-Ch, with the light absorption maxima corresponding to the surface plasmon
31
32 resonance located at 426 nm. This single peak, clearly defined in both cases, is
33
34 representative of globular particles, with a narrow distribution of sizes and homogeneity
35
36 in particle shape. The position and shape of the surface plasmon absorption band is
37
38 similar to those found by other authors [28-30]. In the case of several geometries or
39
40 bimodal size distribution, more peaks appear at different wavelengths. The different
41
42 intensity between the peaks of HA/nAg-Th (thermally reduced) and HA/nAg-Ch
43
44 (chemically reduced) may be related to the number of particles (which is higher in the
45
46 case of HA/nAg-Ch), and the possible presence of silver deposits in HA/nAg-Th.
47
48
49
50
51
52
53
54

55 Fig. 6A and Fig. 6B show some TEM images for HA/nAg-Th and HA/nAg-Ch,
56
57 respectively. In both cases, in the samples obtained by both reduction procedures, the
58
59
60
61
62
63
64
65

1 silver nanoparticles appear perfectly isolated and attached to the surface of the
2 hydroxyapatite particles. The HA matrix acts as an effective scaffold where the
3 nanoparticles are dispersed, avoiding their agglomeration. This is an important feature
4 because a larger contact surface between silver and the microorganisms is expected to
5 increase the bactericidal activity of the composite. Therefore, the small size of the silver
6 nanoparticles ensures that a significantly large surface area is in contact with the
7 microorganisms. It is also possible to observe the globular shape of the particles, in
8 agreement with the information obtained from the surface plasmon.
9

10
11 It can be roughly inferred from numerous TEM micrographs that the average
12 particle size of the silver nanoparticles is below 10 nm. A size distribution was carried
13 out to study this issue and the information is shown Fig. 7. The parameter d_{90} is 15.96
14 nm and 10.01 nm for HA/nAg-Th and HA/nAg-Ch, respectively.
15
16

17
18 The average size of the Ag nanoparticles in the case of HA/nAg-Ch (chemically
19 reduced samples) was 7.02 nm, slightly below that corresponding to the HA/nAg-Th
20 sample (thermally reduced samples), 8.85 nm. Therefore, the bacterial activity of
21 HA/nAg-Ch might have been higher than that of HA/nAg-Th, due to the smaller silver
22 nanoparticles. In order to test this hypothesis, it was necessary to test the bacterial
23 activity of both types of samples in the laboratory.
24
25

26
27 The logarithmic reduction rate ($\log \eta$) was used to evaluate the bacterial activity
28 of the samples. During the test, the viable microorganisms were counted after 24 and 48
29 hours. Fig. 8 shows the results for both samples and compares them with a commercial
30 broad-spectrum antibacterial material [31]. Pure HA was tested as a control, showing no
31 activity. Regarding the activity against bacteria, there was a high activity in both
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 samples, well above the commercial level (marked in Fig. 8 with discontinuous line),
2
3 and there was no difference between the activity of HA/nAg-Th and HA/nAg-Ch.
4
5 However, in the case of yeast (*I. Orientalis*), only HA/nAg-Ch exceeded the
6
7 disinfection limit of a commercial antimicrobial product, showing a more effective
8
9 behavior. The lower effectiveness of the samples against the yeast may be related to the
10
11 different external membrane structure of the cells [32].
12
13
14
15

16
17 Other composite materials with silver nanoparticles have been found in the
18
19 literature and show effectiveness against bacteria while are inactive against yeast [33].
20
21 As shown in Fig. 8, the HA/nAg composite is effective against both kinds of
22
23 microorganisms.
24
25
26

27
28 Fig. 9 shows a sequence in chronological order of four TEM micrographs during
29
30 the treatment of *E. coli* with HA/nAg-Ch. The Ag nanoparticles in contact with the
31
32 membrane caused permeability and, subsequently, cell death [34]. At the beginning of
33
34 the process (Fig. 9A), the particles are attached to the bacteria surface. The next step is
35
36 the rupture of the cellular membrane (Fig. 9B), that enabled the penetration of the
37
38 particles inside the bacteria and it was also possible to observe the destruction of the
39
40 microorganism (Fig. 9C). Fig. 9D shows the appearance of a dead bacterium with the
41
42 membrane completely ruptured. Therefore, this sequence corroborates that the
43
44 membrane is one of the attack points of the silver nanoparticles.
45
46
47
48
49

50
51 Moreover, silver cations, Ag^+ , are more aggressive against cell tissues than
52
53 metallic silver, Ag^0 . For this reason, in order to determine whether silver was in the
54
55 liquid in the form of either cationic silver or metallic silver, the liquid was analyzed by
56
57 UV-VIS spectroscopy. In Fig. 10 the curves corresponding to the surface plasmon
58
59
60
61
62
63
64
65

1 resonance are shown and it is possible to assert that the silver present is in metallic form
2
3 and, therefore, the possible risks are minimized.
4
5

6 7 **4. Conclusions** 8 9

10 This work presents the synthesis and antimicrobial study of a set of
11 hydroxyapatite/silver nanocomposites. Firstly, a method for the synthesis of the HA
12 nanopowder was presented. Subsequently, two different methods for the addition of a
13 second phase consisting in silver nanoparticles were tested: the first one followed a
14 thermal reduction and the second one a chemical reduction. In both cases, the silver
15 nanoparticles were perfectly isolated and attached to the surface of the hydroxyapatite.
16
17 Regarding the activity against bacteria, there was a high activity in both samples;
18 however, in the case of yeast, only the chemically reduced sample (HA/nAg-Ch)
19 exceeded the disinfection limit of a commercial antimicrobial product. The combination
20 of the bioactivity of the ceramic matrix with the biocide activity of the silver
21 nanoparticles makes this material an excellent candidate for implants, bone filling and
22 reconstructive surgery applications. In conclusion, this work demonstrates the
23 effectiveness of the material as biocide and the low risk in its use in bone-related
24 applications.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Acknowledgements** 46 47

48 This work was supported by the Spanish Ministry of Science and Innovation
49 (MICINN) under the project MAT2009-14542-C02 and by the Spanish National
50 Research Council (CSIC) under the PIE Project 200860I118. Miriam Miranda has been
51 supported by the Government of the Principality of Asturias under the *Severo Ochoa*
52 Program.
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- [1] Torrecillas RR, Moya JS, Diaz LA, Bartolome JF, Fernandez A and Lopez-Esteban S. Nanotechnology in joint replacement. Wiley Interdisciplinary Reviews: Nanomedicine. 2007;1:540-52.
- [2] Chen W, Liu Y, Courtney HS, Bettenga M, Agrawal CM, Bumgardner JD and Ong JL. In vitro anti-bacterial and biological properties of magnetron co-sputtered silver-containing hydroxyapatite coating. Biomaterials. 2006;27:5512-7.
- [3] Socransky SS and Haffajee AD. Dental biofilms: difficult therapeutic targets. Periodontology. 2002;28:12-55.
- [4] Patel R. Biofilms and Antimicrobial Resistance. Clinical Orthopaedics and Related Research. 2005;437:41-7.
- [5] Moya JS, Lopez-Esteban S and Pecharroman C. The challenge of ceramic/metal (micro- and nano-) composites. Prog. Mater. Sci. 2007;52:1017–90.
- [6] Fahrenholtz WG, Ellerby DT and Loehman RE. Al₂O₃-Ni Composites with High Strength and Fracture Toughness. Journal of the American Ceramic Society. 2000;83:1279–80.
- [7] Williamson RL, Bruck HA, Wang XL, Watkins TR, Feng YZ and Clarke DR. Residual Strains in an Al₂O₃-Ni Joint Bonded with a Composite. Interlayer Journal of the American Ceramic Society. 1998;81:1541-9.
- [8] Diaz M, Bartolomé JF, Requena J and Moya JS. Wet processing of mullite/molybdenum composites. Journal of the European Ceramic Society. 2000;20:1907-14.
- [9] Wildan M, Edrees HJ and Hendry A. Ceramic matrix composites of zirconia reinforced with metal particles. Materials Chemistry and Physics. 2002;75:276-83.

- 1 [10] Xiang X, Zu XT, Zhu S and Wang LM. Optical properties of metallic nanoparticles
2
3 in Ni-ion-implanted α -Al₂O₃ single crystals. Applied Physics Letters. 2004;84:52-4.
4
5 [11] Díaz M, Barba F, Miranda M, Guitián F, Torrecillas R and Moya JS. Synthesis and
6 Antimicrobial Activity of a Silver-Hydroxyapatite Nanocomposite. Journal of
7
8 Nanomaterials. 2009:498505.
9
10 [12] Miranda M, Fernández A, Díaz M, Esteban-Tejeda L, López-Esteban S, Malpartida
11
12 F, Torrecillas R and Moya JS. Silver-hydroxyapatite nanocomposites as bactericidal and
13
14 fungicidal materials. Int. J. Mat. Res. 2010;101:1.
15
16 [13] Legerps RZ, Traity OR, Legeros JP, Edward K and Shirra WP. Apatite Crystallites:
17
18 Effects of Carbonate on Morphology. Science. 1967;155:1409-11.
19
20 [14] Noro T and Ito K. Biomechanical behavior of hydroxyapatite as bone substitute
21
22 material in a loaded implant model. On the surface strain measurement and the
23
24 maximum compression strength determination of material crash. Bio-Medical Materials
25
26 and Engineering. 1999;9:319-24.
27
28 [15] Ylinen P, Raekallio M, Taurio R, Vihtonen R, Vainionpää S, Partio EK, Törmälä P
29
30 and Rokkanen P. Coralline hydroxyapatite reinforced with polylactide fibres in lumbar
31
32 interbody implantation. Journal of Materials Science: Materials in Medicine.
33
34 2005;16:325-31.
35
36 [16] Hao L, Savalani MM, Zhang Y, Tanner KE, Heath RJ and Harris RA.
37
38 Characterization of Selective Laser-Sintered Hydroxyapatite-Based Biocomposite
39
40 Structures for Bone Replacement. Proceedings: Mathematical, Physical and
41
42 Engineering Sciences. 2007;463:1857-69.
43
44 [17] Palazzo B, Sidoti MC, Roveri N, Tampieri A, Sandri M, Bertolazzi L, Galbusera F,
45
46 Dubini G, Vena P and Contro R. Controlled drug delivery from porous hydroxyapatite
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

grafts: An experimental and theoretical approach. *Materials Science and Engineering: C*. 2005;25:207-13.

[18] Krisanapiboon A, Buranapanitkit B and Oungbho B. Biocompatibility of hydroxyapatite composite as a local drug delivery system. *Journal of Orthopaedic Surgery*. 2006;14:315-8.

[19] Ravelingien M, Smets N, Mullens S, Luyten J, Vervaeck C and Remon JP. Local drug delivery from hydroxyapatite ceramic fibres. 4th European Conference of the International Federation for Medical and Biological Engineering, IFMBE Proceedings. 2009;22:2269-72.

[20] Venugopal J, Prabhakaran MP, Zhang Y, Low S, Choon AT and Ramakrishna S. Biomimetic hydroxyapatite-containing composite nanofibrous substrates for bone tissue engineering. *Philosophical Transactions of the Royal Society A*. 2010;368:2065-81.

[21] Qian P, Jiang F, Huang P, Zhou S, Weng J, Bao C, Zhang C and Yu H. A novel porous bioceramics scaffold by accumulating hydroxyapatite spherules for large bone tissue engineering in vivo. I. Preparation and characterization of scaffold. *Journal of Biomedical Materials Research Part A*. 2010;93A:920-9.

[22] Bonfield W. Designing Porous Scaffolds for Tissue Engineering. *Philosophical Transactions: Mathematical, Physical and Engineering Sciences*. 2006;364:227-32.

[23] Liu JK, Yang XH and Tian XG. Preparation of silver/hydroxyapatite nanocomposite spheres. *Powder Technology*. 2008;184:21-4.

[24] Percival SL, Bowler PG and Russell D. Bacterial resistance to silver in wound care. *Journal of Hospital Infection*. 2005;60:1-7.

- 1 [25] Pourbaix M. Atlas of electrochemical equilibria in aqueous solutions. Houston
2 (Texas). National Association of corrosion Engineers. 1974.
3
4
5
6 [26] Thomas S, Nair SK, Jamal EMA, Al-Harhi SH, Varma MR and Anantharaman
7 MR. Size-dependent surface plasmon resonance in silver silica nanocomposites.
8 Nanotechnology. 2008;19:075710.
9
10
11
12 [27] Esteban-Cubillo A, Diaz C, Fernandez A, Diaz LA, Pecharroman C, TorrecillasR
13 and MoyaJS. Silver nanoparticles supported on α -, η - and δ -alumina. J. Eur. Ceram.
14 Soc. 2006;26:1-7.
15
16
17
18 [28] Arumugan SK, Sastry TP, Sreedhar B and Mandal AB. One step synthesis of silver
19 nanorods by autoreduction of aqueous silver ions with hydroxyapatite: An inorganic-
20 inorganic hybrid nanocomposite. J. Biomed. Mater. Res. Part A. 2007;80A:391-8.
21
22
23
24 [29] Pal S, Tak YK and Song JM. Does the Antibacterial Activity of Silver
25 Nanoparticles Depend on the Shape of the Nanoparticle? A Study of the Gram-Negative
26 Bacterium Escherichia coli. Applied and Environmental Microbiology. 2007;73:1712-
27 20.
28
29
30
31 [30] Panáček A, Kvítek L, Pucek R, Kolář M, Večeřová R, Pizúrová N, Sharma VK,
32 Nevěčná T and Zbořil R. Silver colloid nanoparticles: synthesis, characterization, and
33 their antibacterial activity. J. Phys. Chem. B. 2006;110:16248-53.
34
35
36
37 [31] Esteban-Cubillo A, Pecharromán C, Aguilar E, Santarén J and Moya JS.
38 Antibacterial activity of copper monodispersed nanoparticles into sepiolite. J. Mater.
39 Sci. 2006;41:5208-12.
40
41
42
43 [32] Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, Lee HJ, Kim SH, Park YK, Park YH,
44 Hwang CY, Kim YK, Lee YS, Jeong DH and Cho MH. Antimicrobial effects of silver
45 nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine. 2007;3:95-101.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 [33] Cabal B, Torrecillas R, Malpartida F and Moya JS. Heterogeneous precipitation of
2 silver nanoparticles on kaolinite plates. *Nanotechnology*. 2010:475705.
3

4
5 [34] Sondi I and Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case
6 study on *E. coli* as a model for Gram-negative bacteria. *J. Colloid. Interface Sci.*
7
8 2004;275:177-82.
9

10
11 [35] Ayala-Núñez N, Lara Villegas H, del Carmen Ixtepan Turrent L and Rodríguez
12 Padilla C. Silver Nanoparticles Toxicity and Bactericidal Effect Against Methicillin-
13 Resistant *Staphylococcus aureus*: Nanoscale Does Matter. *NanoBioTechnology*.
14
15 2009;5:2-9.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 **Figure Captations**

2
3 **Fig. 1 A.** Synthesis of pure hydroxyapatite nanopowder. **B.** Synthesis of HA/nAg
4 composite nanopowder
5

6
7
8 **Fig. 2** HA solubility curve for different pH values
9

10
11 **Fig. 3 A.** TG/DTA curves to determine the conditions of the heat treatment to obtain
12 HA powder. **B.** X-ray diffractograms for samples calcined at 300°C, 475°C and 550°C,
13 leading to amorphous HA, partially amorphous HA and crystalline HA, respectively
14
15

16
17
18 **Fig. 4 A.** Particle size distribution of the HA powder. **B.** TEM micrograph showing the
19 size and morphology of the HA nanoparticles synthesized and detail of the
20 crystallographic planes
21
22

23
24
25 **Fig. 5 A.** XRD graphics for both samples of HA with nAg. **B.** UV-vis spectrum of the
26 HA/nAg samples showing the surface plasmon band of silver nanoparticles in both
27 samples
28
29

30
31
32 **Fig. 6 A.** TEM micrographs of the thermally reduced sample, HA/nAg-Th. **B.** TEM
33 micrographs of the chemically reduced sample, HA/nAg-Ch, and detail of a Ag-
34 nanoparticle attached to the surface of a HA particle
35
36

37
38
39
40 **Fig. 7** Particle size distribution of silver nanoparticles obtained by both reduction
41 methods
42
43


44
45 **Fig. 8** Logarithm reduction used to characterize the effectiveness of the biocide agent
46 for bacteria *E. coli*, *M. luteus* and yeast *I. orientalis* studied at 24 and 48 hours
47
48

49
50 **Fig. 9A-D** TEM micrographs showing the sequence of stages when *E. coli* is exposed to
51 HA/nAg powder
52
53

54
55 **Fig. 10** Curves corresponding to the surface plasmon resonance of silver in the
56 lixiviated liquid of HA/nAg-Ch
57
58
59
60
61
62
63
64
65

Figure1
[Click here to download high resolution image](#)

A)



B)




Figure2
[Click here to download high resolution image](#)




Figure3A
[Click here to download high resolution image](#)




Figure3B
[Click here to download high resolution image](#)




Figure4A
[Click here to download high resolution image](#)





Figure 4B
[Click here to download high resolution image](#)






Figure5B
[Click here to download high resolution image](#)




Figure6A
[Click here to download high resolution image](#)




Figure6B
[Click here to download high resolution image](#)




Figure7
[Click here to download high resolution image](#)





Figure8
[Click here to download high resolution image](#)



* $\text{Log } \eta = \text{Log (control microorganisms)} - \text{Log (sample microorganisms)}$
- - - Commercial broad-spectrum antibacterial/antimicrobial

Figure9
[Click here to download high resolution image](#)




Figure10
[Click here to download high resolution image](#)




Table 1. Particle size distribution of silver nanoparticles obtained by different dry processes.

Sample	Dry treatment	Size (nm)	D₉₀
HA/nAg-Ch-60	60°C	9.7±3.8	15.9
HA/nAg-Ch-150	150°C	9.9±2.2	16.7
HA/nAg-Ch-250	250°C	8.9±3.1	11.1
HA/nAg-Ch-L	Lyophilization	7.0±2.8	10.1

Table 2. Silver concentration measured in the lixiviated liquid after the biocide tests.

	HA/nAg-Th		HA/nAg-Ch	
	Ag concentration (ppm)	pH	Ag concentration (ppm)	pH
<i>E. Coli</i>	1.981	6.716	1.184	6.57
<i>M. Luteous</i>	1.199	7.030	1.342	6.93
<i>I. Orientalis</i>	0.008	6.733	1.614	6.64